ANA LUCIA BELTRATI CORNACCHIONI
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients(2015) HAMERSCHLAK, Nelson; SOUZA, Carmino de; CORNACCHIONI, Ana Lúcia; PASQUINI, Ricardo; TABAK, Daniel; SPECTOR, Nelson; STEAGALL, MerulaCONTEXT AND OBJECTIVES: Chronic myeloid leukemia (CML) requires strict daily compliance with oral medication and regular blood and bone marrow control tests. The objective was to evaluate CML patients' perceptions about the disease, their access to information regarding the diagnosis, monitoring and treatment, adverse effects and associations of these variables with patients' demographics, region and healthcare access. DESIGN AND SETTING: Prospective cross-sectional study among CML patients registered with the Brazilian Lymphoma and Leukemia Association (ABRALE). METHODS: CML patients receiving treatment through the public healthcare system were interviewed by telephone. RESULTS: Among 1,102 patients interviewed, the symptoms most frequently leading them to seek medical care were weakness or fatigue. One third were diagnosed by means of routine tests. The time that elapsed between first symptoms and seeking medical care was 42.28 ± 154.21 days. Most patients had been tested at least once for Philadelphia chromosome, but 43.2% did not know the results. 64.8% had had polymerase chain reaction testing for the BCR/ABL gene every three months. 47% believed that CML could be controlled, but 33.1% believed that there was no treatment. About 24% reported occasionally stopping their medication. Imatinib was associated with nausea, cramps and muscle pain. Self-reported treatment adherence was significantly associated with normalized blood count, and positively associated with imatinib. CONCLUSIONS: There is a lack of information or understanding about disease monitoring tools among Brazilian CML patients; they are diagnosed quickly and have good access to treatment. Correct comprehension of CML control tools is impaired in Brazilian patients.
conferenceObject LONG TERM COMPLICATIONS IN CHILDREN TREATED FOR ADVANCED NEUROBLASTOMA(2012) HALLEY, Nathalia; CRISTOFANI, Lilian Maria; ALMEIDA, Maria Teresa Assis; MALUF-JUNIOR, Paulo Taufi; CORNACCHIONI, Ana Lucia Beltrati; TEIXEIRA, Roberto Augusto Plaza; ZAMPERLINI-NETO, Gabriele; GOMES, Alessandra Araujo; ODONE-FILHO, VicentePurpose: Advanced neuroblastoma (stage 3 and 4) requires aggressive treatment, including surgery, chemo and radiotherapy and autologous bone marrow transplantation. Although long term survival rates are disappointing, those children who survive are prone to develop long term complications. Our aim is to report the long term complications rate and quality in children treated for stage 3 and 4 neuroblastoma. Methods: The charts of stage 3 and 4 children with neuroblastoma treated from January/1983 through October/2003 were reviewed and those surviving and with no evidence of disease for more than 5 years were selected. Late effects were classified as second malignancies, endocrinological, neuromotor, hepatic, sensorial, benign tumors, infectious diseases and psychiatric disease and others. Associations with treatment modalities were disclosed. Results: Among 263 children with stage 3 and 4 neuroblastoma, 40 (15%) are long term survivors. 20/40 (50%) present one or more complications, being 2 (10%) second malignant neoplasia, 4 (20%) endocrinological disturbances, 4 (20%) neuromotor, 5 (25%) hepatic, 4 (20%) sensorial, 3 (1.1%) benign tumors, and infertility, psychiatric disease and hepatitis C infection in 1 (5%) episode each. 10/20 (50%) of the children were less than 18 months at diagnosis, and 12/20 (60%) were stage 3 and 8/20 (40%) were stage 4. All children were submitted to chemotherapy and 7/20 (35%) to autologous bone marrow transplantation. In 10/20 (50%) patients radiotherapy was also included, and 4/10 (40%) presented functional lesions in the irradiated field. All endocrinologic sequelae were detected in the ABMT group. Second malignant neoplasia were not related to RDT(1 ALL and 1 thyroid carcinoma). Conclusion: Children surviving aggressive therapy for neuroblastoma are at risk of late effects, particularly endocrinological and neurological complications, requiring close observation to prompt intervention when necessary, avoiding impairments in quality of life or even life threatening situations. Second malignant neoplasia require special concern.conferenceObject CD8 Positive T Cell Number as Indicator of Prognosis in Children with Relapsed or Primarily Refractory Cancer(2018) ODONE-FILHO, V.; CRISTOFANI, L. M.; TEIXEIRA, R. A.; GIMENEZ, T. M.; SANTOS, A. R.; MARCHI, F. A.; LAPA, R. L.; KREPISCHI, A. C.; NOVAK, L. M.; BRUMATTI, M.; PEREIRA, P. L.; AZAMBUJA, A. M.; DORIA-FILHO, U.; CORNACHIONNI, A. L.; VINCE, C. S.; NEVES, N. H.conferenceObject SHORT STATURE IN PEDIATRIC CANCER SURVIVORS(2017) ITO, Simone S.; ATHAYDE, Debora A. M.; MARTIN, Selma R. C. San; FRANCO, Natalia C. F.; DUARTE, Nathalia F. V.; CRISTOFANI, Lilian M.; CORNACHIONI, Ana Lucia; KUPERMAN, Hilton; ODONE FILHO, Vicente; DAMIANI, Durval- Comparative study of quality of life of adult survivors of childhood acute lymphocytic leukemia and Wilms’ tumor(2015) SOUZA, Clélia Marta Casellato de; CRISTOFANI, Lilian Maria; CORNACCHIONI, Ana Lucia Beltrati; ODONE FILHO, Vicente; KUCZYNSKI, EvelynAbstract Objective To analyze and compare the health-related quality of life of adult survivors of acute lymphocytic leukemia and Wilms’ tumor amongst themselves and in relation to healthy participants. Methods Ninety participants aged above 18 years were selected and divided into three groups, each comprising 30 individuals. The Control Group was composed of physically healthy subjects, with no cancer history; and there were two experimental groups: those diagnosed as acute lymphocytic leukemia, and those as Wilms’ Tumor. Quality of life was assessed over the telephone, using the Medical Outcomes Study 36-Item Short Form Health Survey. Results Male survivors presented with better results as compared to female survivors and controls in the Vitality domain, for acute lymphocytic leukemia (p=0.042) and Wilms’ tumor (p=0.013). For acute lymphocytic leukemia survivors, in Social aspects (p=0.031), Mental health (p=0.041), and Emotional aspects (p=0.040), the latter also for survivors of Wilms’ tumor (p=0.040). The best results related to the Functional capacity domain were recorded for the experimental group that had a late diagnosis of acute lymphocytic leukemia. There were significant differences between groups except for the Social and Emotional domains for self-perceived health, with positive responses that characterized their health as good, very good, and excellent. Conclusion Survivors of acute lymphocytic leukemia showed no evidence of relevant impairment of health-related quality of life. The Medical Outcomes Study 36-Item Short Form Health Survey (via telephone) can be a resource to access and evaluate survivors.
- Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor(2014) HAMERSCHLAK, Nelson; SOUZA, Carmino de; CORNACCHIONI, Ana Lucia; PASQUINI, Ricardo; TABAK, Daniel; SPECTOR, Nelson; STEAGALL, MerulaThe purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. The mean QOL among CML patients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p = 0.012) and leukemia-specific score (p = 0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p > 0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p < 0.001, Spearman's correlation). The use of imatinib (p = 0.012) was associated with a better ability to work, while chemotherapy (p = 0.017) and the use of hydroxyurea (p = 0.001) were inversely associated with work capability. A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment.
conferenceObject Complete Control of a Post-Transplant Monomorphic Lymphoproliferative Disorder (PTMLD) with the Sole Use of Hydroxyurea (HY)(2018) ODONE-FILHO, V.; TEIXEIRA, R. A.; CRISTOFANI, L. M.; VINCE, C.; CORNACCHIONI, A. L.; RICARDI, L. R.; MALUF, P.; ALMEIDA, M. T.; FRANCA, C.; PEREIRA, P.; AZAMBUJA, A.